AOD-9604 vs Mazdutide
Side-by-side comparison of key properties, dosing, and research.
- Summary
- AOD-9604 is a modified fragment of human growth hormone (residues 177-191) with an additional tyrosine residue that significantly enhances bioavailability. Originally developed as an anti-obesity drug by Metabolic Pharmaceuticals, it stimulates lipolysis and inhibits lipogenesis without the diabetogenic effects of full GH.
- Mazdutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Innovent Biologics and Eli Lilly. Phase 2 trials in Chinese populations demonstrated up to 11.3% body weight reduction at 6 mg over 24 weeks. It also improves liver fat, glycemic control, and lipid profiles. Phase 3 trials are ongoing primarily in China.
- Half-Life
- 30-45 minutes injectable; longer with nasal spray formulation
- ~7 days
- Admin Route
- SubQ, Intranasal, Oral
- SubQ
- Research
- —
- —
- Typical Dose
- 300-600 mcg
- 1.5 mg → 3 mg → 4.5 mg → 6 mg
- Frequency
- Once daily
- Once weekly
- Key Benefits
- Selective fat loss without anabolic side effects
- No effect on blood glucose or insulin resistance
- Improved bioavailability over Fragment 176-191
- GRAS (Generally Recognized As Safe) status in Australia
- Potential cartilage repair and anti-inflammatory properties
- Does not suppress natural GH production
- Up to 11.3% body weight reduction at 24 weeks (Phase 2, 6 mg dose)
- Significant reduction in liver fat content (NAFLD/MASH potential)
- Improves HbA1c and fasting glucose in type 2 diabetes
- Favorable lipid profile changes (reduced triglycerides)
- Once-weekly subcutaneous dosing
- Potential for superior weight loss vs GLP-1 monotherapy
- Side Effects
- Localized injection site reactions
- Headache (rare)
- Hypoglycemia risk in combination with insulin (very rare)
- Nausea
- Vomiting
- Decreased appetite
- Diarrhea
- +3 more
- Stacks With
- —
- —